Lakefront Biotherapeutics (LKFT) Revenue (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Revenue for 13 consecutive years, with $7.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Revenue fell 90.38% year-over-year to $7.6 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 398.27% YoY), while the FY2025 annual figure was $1.3 billion, up 339.54% from the prior year.
• Revenue slipped to $7.6 million in Q1 2026 per LKFT's latest filing, from $1.0 billion in the prior quarter.
• Across five years, Revenue topped out at $1.0 billion in Q4 2025 and bottomed at -$55.1 million in Q2 2024.
• Historically, Revenue has averaged $122.9 million across 5 years, with a median of $66.6 million in 2023.
• Annual changes were most pronounced in 2024 — Revenue slumped 184.3% — and 2025, when it surged 8432.91%.
• Lakefront Biotherapeutics' Revenue stood at $184.4 million in 2022, then plunged by 34.48% to $120.8 million in 2023, then sank by 89.83% to $12.3 million in 2024, then soared by 8432.91% to $1.0 billion in 2025, then tumbled by 99.28% to $7.6 million in 2026.
• Business Quant data shows LKFT's Revenue at $7.6 million in Q1 2026, $1.0 billion in Q4 2025, and $83.2 million in Q3 2025.